Journal Scans
Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group
Selective Benefit of Androgen Suppression With RT in Prostate Cancer
PL Nguyen, M-H Chen, CJ Beard, WW Suh, AA Renshaw, M Loffredo, E McMahon, PW Kantoff, AV D'Amico
20100601
2010 Jul 1
Int J Radiat Oncol Biol Phys
Radiation With or Without 6 Months of Androgen Suppression Therapy in Intermediate- and High-Risk Clinically Localized Prostate Cancer: A Postrandomization Analysis by Risk Group
Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(4):1046-1052, PL Nguyen, M-H Chen, CJ Beard, WW Suh, AA Renshaw, M Loffredo, E McMahon, PW Kantoff, AV D'Amico
TAKE-HOME MESSAGE
Abstract
Abstract
Purpose: Six months of androgen suppression therapy (AST) plus radiation (RT) prolongs survival vs. RT alone in men with unfavorable risk localized prostate cancer (PCa), but it is unknown if this benefit applies to all risk subgroups and, in particular, the intermediate-risk group. Methods and Materials: Among 206 men with stages T1b to T2b PCa and either a prostate-specific antigen level of >10 or a Gleason score of ≥7 or MRI evidence of T3 disease randomized to receive 70 Gy of RT with or without...
